zum Inhalt
Header Image

Herausforderungen der biomedizinischen Forschung

-
Erwin-Schrödinger-Saal
Plenary / Panel
in englischer Sprache

Die biomedizinische Forschung ist eine wichtige Voraussetzung zur Erkennung der inneren molekularen Strukturen und ihrer Wechselwirkungen. Allerdings steigen mit jeder neuen Erkenntnis auch die Komplexität der Verursachung und damit die Chancen der Heilungsprozesse. Welche Durchbrüche durch neue Therapieverfahren Anlass zu neuer Hoffnung geben, ist Gegenstand dieses Plenums.

Vortragende

Research Group Leader, IMBA - Institute of Molecular Biotechnology, Vienna
Nobel Laureate in Chemistry; Cecil H. and Ida M. Green Professor of Structural Biology, The Scripps Research Institute; Professor of Biophysics, Institute for Molecular Biology and Biophysics, Swiss Federal Institute of Technology, Zurich Abstract
The determination of the human genome and the genomes of a large number of other species has awakened big expectations in many different fields, including in particular also healthcare. May of these anticipated advances will have to be based on additional detailed knowledge of the proteome and other gene products of the organisms of interest. Envisaged goals of „structural genomics“ are therefore to increase coverage of the protein universe derived from the DNA sequences with three-dimensional protein structures, and to use newly determined structures of previously unknown proteins („domains of unknown function“, DUFs) for gaining novel insights into the chemical biology of the living cell, which can then contribute to an extended platform for rational, structure-based drug design. My research team makes use of nuclear magnetic resonance (NMR) spectroscopy for atomic-resolution structure determination of proteins, nucleic acids and their complexes at solution conditions close to the physiological milieu in body fluids. Illustrations with recent studies of G-protein-coupled receptors (GPCRs) [1,2], which are targets for more than 30% of the presently available prescription drugs in human medicine, will be used to indicate future potentialities and challenges for structural biology in biomedical research.

References:
[1] Liu, J.J., Horst, R., Katritch, V., Stevens, R.C. and Wüthrich, K. (2012) Science 335, 1106-1110.
Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR.

[2] Stevens, R.C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H. and Wüthrich, K. (2013) Nat. Rev.Drug Disc. 12, 1-10.
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function.
Research Group Leader, IMP - Research Institute of Molecular Pathology, Vienna
Scientific Managing Director, AIT Austrian Institute of Technology GmbH, Vienna Chair

Ph.D. Julius Fabian BRENNECKE

Research Group Leader, IMBA - Institute of Molecular Biotechnology, Vienna

1995-2000 Diploma Studies in Biology; Heidelberg
2001-2004 PhD thesis at the EMBL Heidelberg
2005-2006 PostDoc at the EMBL Heidelberg
2006-2008 PostDoc at Cold Spring Harbor Laboratories
since 2009 Group Leader at the Institute for Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences

Dr. Dr. h.c. (mult.) Kurt WÜTHRICH

Nobel Laureate in Chemistry; Cecil H. and Ida M. Green Professor of Structural Biology, The Scripps Research Institute; Professor of Biophysics, Institute for Molecular Biology and Biophysics, Swiss Federal Institute of Technology, Zurich

1957-1962 Lizentiat in chemistry, physics and mathematics, University of Bern, Switzerland
1962-1964 Ph.D. in chemistry (Prof. S. Fallab); Eidgenössisches Turn- und Sportlehrerdiplom, University of Basel, Switzerland
1964-1965 Postdoctoral training (Prof. S. Fallab), University of Basel, Switzerland
1965-1967 Postdoctoral training (Prof. R.E. Connick), University of California, Berkeley, CA, USA
1967-1969 Member Technical Staff, Biophysics Department (Dr. R.G. Shulman), Bell Telephone Laboratories, Murray Hill, N.J., USA
1969 Privatdozent (1970), Assistant Professor (1972), Associate Professor (1976), Professor of Biophysics (1980); Chairman Biology Department (1995 2000), ETH Zurich, Switzerland
2001-2004 Cecil H. and Ida M. Green Visiting Professor of Structural Biology, The Scripps Research Institute, La Jolla, CA, USA
since 2004 Cecil H. and Ida M. Green Professor of Structural Biology, The Scripps Research Institute, La Jolla, CA, USA

Dr. Johannes ZUBER

Research Group Leader, IMP - Research Institute of Molecular Pathology, Vienna

  Clinical training in general oncology, hematology and hemostaseology, high-dose chemotherapy, stem-cell transplantation and intensive care medicine
2001-2005 Clinical Internship & Residency (Arzt im Praktikum & Assistenzarzt) in Hematology and Oncology, Charité University Hospital, Berlin
  Development of genetically engineered leukemia mouse models; studies on mechanisms in leukemogenesis and drug resistance; RNAi technology (new vector systems, RNAi Sensor assay, in-vivo RNAi screening, custom shRNA libraries)
2005-2008 Postdoctoral Research Fellow, Laboratory of Scott W. Lowe, PhD Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  In-vivo RNAi studies in leukemia mouse models and transgenic RNAi models. Multiplexed negative-selection RNAi screening, RNAi-based in-vivo validation of candidate therapeutic targets. Chromatin regulators in leukemia maintenance
2009-2010 Clinical Research Fellow, Cold Spring Harbor Laboratory, New York
since 2011 Research Group Leader, IMP - Research Institute of Molecular Pathology, Vienna

Dr. Wolfgang KNOLL

Scientific Managing Director, AIT Austrian Institute of Technology GmbH, Vienna

1973 Diploma Physics, Karlsruhe Institute of Technology
1976 Ph.D., Biophysics, University of Konstanz
1976-1977 Postdoctoral Fellow, University of Konstanz
1977-1980 Postdoctoral Fellow, University of Ulm
1980-1981 Postdoctoral Fellow, IBM Research Laboratory, San José, CA
1981 Visiting Scientist, Institute Laue-Langevin, Grenoble
1981-1986 Assistant Professor, Technical University of Munich
1985 Visiting Scientist, IBM Research Laboratory, San José, CA
1986 Postdoctoral Degree: "Habilitation" - Physics, Technical University of Munich
1986-1991 Young Investigator/Associate Professor, Max Planck Institute for Polymer Research, Mainz
1988 Visiting Scientist, Optical Sciences Center, Tucson, AZ
1990 Visiting Scientist, Dept. of Chem. & Nuc. Engineering, University of California, Santa Barbara, CA
1990-1991 Visiting Professor, University of Erlangen
1991-1999 Head of Laboratory, Exotic Nano-Materials, Frontier Research Program, RIKEN-Institute, Japan
since 1992 Consulting Professor, Department of Chemical Engineering, Stanford University, Stanford, CA
1993-2008 Director, Max-Planck-Institut für Polymerforschung, Mainz
since 1998 Professor (by Courtesy) Chemistry Department, University of Florida, Gainesville, FL
since 1999 Adjunct Professor, Hanyang University, Korea
1999-2003 Temasek Professor, National University of Singapore
2004-2013 Visiting Principal Scientist, Institute of Materials Research and Engineering, Singapore
since 2008 Scientific Managing Director, AIT Austrian Institute of Technology GmbH, Vienna
since 2009 Honorary Professor, University of Natural Resources and Applied Life Sciences, Vienna
since 2009 Visiting Professor, Nanyang Technological University, Singapore

Technologiegespräche

Timetable einblenden

22.08.2013

10:00 - 12:30Technologiebrunch gegeben von Standortagentur TirolPartner
13:00 - 13:10Eröffnung der Alpbacher Technologiegespräche 2013Plenary
13:10 - 13:45Innovation und PolitikPlenary
13:45 - 15:15Die Zukunft der Innovation - internationale PerspektivenPlenary
15:40 - 16:40Graphen - Hoffnungsträger zukünftiger Technologien?Plenary
16:40 - 18:00Von der Forschung zum wirtschaftlichen ErfolgPlenary
20:00 - 21:45Wir im UniversumPlenary
21:45 - 00:00Abendempfang gegeben von Forschung AustriaSocial
21:45 - 00:00Karrierelounge gegeben von den Veranstaltern und Siemens AG ÖsterreichSocial

23.08.2013

08:30 - 15:00Arbeitskreis 05: Zukunftsraum Alpen: Fokus nachhaltige RessourcennutzungBreakout
09:00 - 15:00Arbeitskreis 01: Die Wertschöpfungsketten der ZukunftBreakout
09:00 - 15:00Arbeitskreis 02: To Develop the Future - Innovation von morgen am Beispiel internationaler LeitbetriebeBreakout
09:00 - 15:00Arbeitskreis 03: Smart City - Wege zur urbanen Mobilität von morgenBreakout
09:00 - 15:00Arbeitskreis 04: "Frontrunner" als neuer Ansatz der FTI-PolitikBreakout
09:00 - 15:00Arbeitskreis 06: Das Potenzial von IKT-Tools im Open Innovation-ProzessBreakout
09:00 - 15:00Arbeitskreis 07: Web attack! Der Kampf gegen Hacker und DatenverlustBreakout
09:00 - 15:00Arbeitskreis 08: Industrie 4.0 - Auswirkungen auf die Arbeitswelt der ZukunftBreakout
09:00 - 15:00Arbeitskreis 09: Green Tech: Vision und Business ECO-MobilitätBreakout
09:00 - 15:00Arbeitskreis 10: Identität 2.0: der digitale MenschBreakout
09:00 - 15:00Arbeitskreis 11: Intellectual Property Management - Voraussetzungen für Wohlstand und ErfolgBreakout
09:00 - 15:00Arbeitskreis 12: Sichere Gesellschaft = Gesicherte Zukunft = SicherheitsforschungBreakout
09:00 - 18:00Junior Alpbach - Wissenschaft und Technologie für junge MenschenBreakout
09:00 - 15:00Sonderveranstaltung: Strategieempfehlungen zur FTI InternationalisierungBreakout
09:00 - 15:00Ö1 Kinderuni Alpbach - Wissenschaft und Technologie für KinderBreakout
16:00 - 17:30i-Learning - Die Zukunft des Lernens in der digitalen WeltPlenary
17:45 - 20:00Herausforderungen der biomedizinischen ForschungPlenary
20:00 - 22:00Open Dialogue - Smarte Mobilität für Smart CitiesPartner

24.08.2013

09:30 - 10:15Innovation planen: Irrwege und AuswegePlenary
10:15 - 12:00Cybercrime und CybersecurityPlenary
12:15 - 13:15Die wunderbare Welt der QuantenmechanikPlenary
13:15 - 13:30Abschluss-Statement der Alpbacher TechnologiegesprächePlenary
13:30 - 14:00Imbiss zum Abschluss der Veranstaltung gegeben von den VeranstalternSocial